Completion↦Quality and Risk↦Clinical Study Report↦Risk Reporting
What is it? Why is it important?
A (final) Clinical Study Report (CSR) is an account describing in detail the methods, events and results of a study. The reporting of the risk management of the study is an important integral part of this document.
The CSR is written after the monitoring close-out visit has taken place, as the study is then closed and ready for the statistical analysis. Among other the report describes:
- The risk-based QMS implemented during the study
- Identified risks including applicable control measures
- Important deviations and remedial actions taken
The SP-INV submits the final CSR to the Ethics Committee (EC) and RA (e.g. Swissmedic), as applicable.
What do I need to do?
Based on the RAF:
- Describe the risk-based QMS implemented in your study
- Summarise important deviations and remedial actions taken
- If you have been audited include the audit certificate
- Complete other report sections and submit the report to the EC and RA (e.g. Swissmedic), as applicable
The CSR must be ready and submitted to the EC no later than 1 year the completion (last visit of the last participant) or discontinuation of the study.
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Departement Klinische Forschung, CTU, dkf.unibas.ch
Lugano, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.usz.ch
References
ICH GCP E6(R2) – see in particular guidelines
- 1.6 Audit
- 5.0 Quality management
ISO 9001 (access liable to costs – see in particular section
- QMS Requirements
Swiss Law
ClinO – see in particular article
- Art 38 Final report